Melissa Leichter Announces The Newly FDA Approved Subcutaneous Prophylactic Treatment for Hemophilia A or B
Melissa Leichter, Rare Disease Executive, Novo Nordisk, shared a proud announcement post on LinkedIn:
”Today marks an exciting step forward for the hemophilia community. The FDA has approved our new subcutaneous prophylactic treatment for patients aged 12 and older living with hemophilia A or B.
This approval builds on our earlier indication for people living with hemophilia with inhibitors and reflects our continued commitment to expanding access and reimagining care across the hemophilia landscape.
Behind this milestone is a team of passionate, driven individuals who work tirelessly to bring innovative solutions to life. I am incredibly proud to be part of this journey—one that’s focused on delivering better options and more control for people navigating life with hemophilia. Thank you to the entire team who has contributed to this great achievement. Your dedication makes a real difference.”
Melissa Leichter proudly shares news on FDA Approvement for Alhemo.
Latest news in the field of Hemophilia Management featured in Hemostasis Today.
-
Aug 3, 2025, 04:27Thomas Reiser Invites You to ISTH’s Engaging Podcasts and YouTube Channel
-
Aug 3, 2025, 04:12Fresh Frozen Facts Part 4: A Thoughtful Look at Plasma Transfusion by Dr. Caitlin Raymond
-
Aug 2, 2025, 19:15WFH Workshop Highlights: Advancing ITI Success and FVIII Optimization in Hemophilia Care
-
Aug 2, 2025, 18:28Filippo Crea Shares Some AI-Insights on Recurrent STEMI
-
Aug 2, 2025, 18:05MSK Cancer Center CME: Expert Insights on Benign Hematology, Hemostasis and Thrombosis
-
Aug 3, 2025, 03:54Cedric Hermans on the Inspiring Impact of the WFH Humanitarian Aid Program Worldwide
-
Aug 2, 2025, 20:14Sebastian Szmit Shares Patients’ Perspectives on Decision‑Making for Antithrombotic Therapy in Advanced Cancer
-
Aug 2, 2025, 19:44Emmanuel J Favaloro Highlights New Publication Marking 100 Years of von Willebrand Disease
-
Aug 2, 2025, 18:53Acute Ischemic Minor Stroke and IV Thrombolysis: Findings from a Danish Nationwide Study
-
Aug 2, 2025, 04:31Acute VTE in Women: Continue Contraception, Select the Right Anticoagulant
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 31, 2025, 15:37Sano Genetics: “Unreasonable” Leadership with Benny Sorenson of Hemab
-
Jul 28, 2025, 12:53Zambia’s Hemophilia Prophylaxis Success
-
Jul 26, 2025, 16:14Cesar Garrido: Forging Strong Partnerships on WHA78 ''Global Health Equity'' Event
-
Jul 23, 2025, 15:34Don't Miss the Hemophilia B Virtual Event on July 29 – Sign Up Now!
-
Jul 23, 2025, 11:05Haemnet Gives Voice to Parents Facing the Challenges of Childhood Bleeding Disorders